Lucence Diagnostics today announced the launch of the world’s first molecular test to distinguish breast fibroadenoma, the commonest benign breast tumor, from phyllodes tumor, a less common tumor that may be malignant. Both fibroadenomas and phyllodes tumors are classified as fibroepithelial tumors. This test will help doctors decide how to treat an indeterminate fibroepithelial breast […]
Related Articles
The post Lucence Diagnostics Launches a first-of-its-kind molecular test to Guide Surgical Approach for Breast Fibroepithelial Tumors appeared first on Biotechin.Asia.
This post first appeared on Biotechin.asia – Your Daily Biotech And Healthca, please read the originial post: here
